Navigation Links
Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
Date:11/18/2013

s. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims.  If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed pro
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2014)... Clarassance, a privately held clinical-stage biotechnology company based ... Therapeutics , Inc. The new name is derived from ... in the lungs similar to branches on a tree), ... therapeutics for the treatment of respiratory diseases. , ... to mark the company's escalation into the clinical phase ...
(Date:12/13/2014)... and TAICHUNG, Taiwan (PRWEB) December 12, 2014 ... less rosy indicators in overall global economic growth, Eugene ... optics and photonics , said in a featured talk ... on 5 December at the National Chung Hsing University ... which is being integrated into future energy supplies and ...
(Date:12/13/2014)... NC (PRWEB) December 13, 2014 According ... 3 million people between now and 2030." If a ... become the seventh most populous state in the country. ... is gathering at the Future of North Carolina Forum ... Ready? Do we have the necessary infrastructure in place? ...
(Date:12/13/2014)...  Vermillion, Inc. (NasdaqCM: VRML), a bio-analytical solutions company focused ... Veronica G. H. Jordan , Ph.D., and David ... bringing the total number of directors to eight, seven ... LaFrance , Chairman, President, and Chief Executive Officer of ... appointments of Veronica and David to our board of ...
Breaking Biology Technology:Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 2Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 3Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 4Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 5North Carolina Chamber of Commerce: Asking Questions & Gathering Answers with a Futurist 2Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber 2Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber 3
... Principle Reached to Terminate Marketing Agreement with Triax ... on Most Favorable Terms, NAPA, Calif., May 15 ... company engaged in the development,of technologies that target the ... quarter ended March 31, 2008 and an agreement in,principle ...
... May 15 Indevus,Pharmaceuticals, Inc. (Nasdaq: IDEV ) ... & Renshaw 5th Annual Global Healthcare Conference on,May 19, ... and at the 2008 UBS,Global Generic and Specialty Pharmaceuticals ... time (5:00 a.m. EDT). The presentations will,be web cast ...
... Mass., May 15 Hologic, Inc. (Nasdaq:,HOLX) today ... be,presenting at the Citigroup Investment Research Global Healthcare,Conference ... the Hilton Hotel in New York,NY., Interested ... audio webcast of,Hologic,s investor presentation on Thursday, May ...
Cached Biology Technology:Senetek PLC Reports First Quarter 2008 Financial Results 2Senetek PLC Reports First Quarter 2008 Financial Results 3Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences 2Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences 3
(Date:12/10/2014)... You,ve been here before: you desperately need to sign into ... key or the answer to your secret question. What,s your ... Today, Hoyos Labs , a digital infrastructure security ... an end to the frustration that comes with usernames, passwords ... a user,s smartphone to acquire his or her biometrics to ...
(Date:12/10/2014)... 9, 2014  Wake Forest Baptist Medical Center today announced ... School of Medicine. Funding for this $50 million capital ... will be publicly launched next summer. ... former 60 series R.J. Reynolds Tobacco Company complex, adjacent ... begin immediately with plans to be ready to welcome ...
(Date:12/10/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ) ... Market in Japan 2014-2018" report to their ... The integration of biometrics and smart ... upgradation of the driver,s license is one of ... the aforementioned projects, biometrics is being used as ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... 2011 Jerusalem, Israel The Israeli Chairmanship of EUREKA, ... innovation, announced today in Jerusalem that since the start ... cooperative R&D projects have been approved and supported by ... Assembled in Jerusalem for the fourth and final event ...
... Chronic stress has long been linked with neurodegeneration. Scientists ... study, which has tremendous implications for understanding and treating Alzheimer,s ... FASEB Journal (the Journal of the Federation ... Kelvin J. A. Davies, the James E. Birren Chair at ...
... University of Cambridge has found a link between impulsivity ... and luck) in problem gamblers. Studying compulsive gamblers ... Clinic, the researchers found that those gamblers with higher ... in reasoning associated with gambling, such as superstitious rituals ...
Cached Biology News:EUREKA invested over 300 million euros in industrial initiatives over the past year 2EUREKA invested over 300 million euros in industrial initiatives over the past year 3EUREKA invested over 300 million euros in industrial initiatives over the past year 4USC scientists uncover mechanism by which chronic stress causes brain disease 2Betting on good luck and 4-leaf clovers 2
... induced prior to DNA purification increasing DNA ... single-copy BACs with the high yields associated ... kits provide the linearized vector and associated ... necessary to create a 10X human BAC ...
Screening assay to detect the Listeria monocytogenes in food samples by,DNA amplification and molecular hybridization on a microtiter plate....
... CopyControl™ vector can be induced prior to ... provide the stability of single-copy BACs with ... other cloning vectors. The kits provide the ... insert size screening system) necessary to create ...
... EPICENTREs patented MasterAmp™ 10X PCR ... performance and allows improved sensitivity and ... templates. Using MasterAmp™ PCR Enhancer in ... of DNA melting, increases enzyme?s thermal ...
Biology Products: